Skip to content

A prospective study on the safety and efficacy of treatment with Qiluxiaobai formula for CKD 2-3 stage

Investigation on the Mechanisms Of Invigorating Spleen Dissipating Dampness Principle On The Treatment Of Podocyte Injury In Focal Segmental Glomerulosclerosis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14005064
Enrollment
Unknown
Registered
2014-08-06
Start date
2014-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

1:basic treatment and losartan K 50mg qd
2:basic treatment and QLXB formula 200ml qd

Sponsors

Shanghai University of T.C.M
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients aged 18~70 years old, which was qi deficiency of kidney and spleen and dampness heat syndrome with syndrome differentiation of TCM. Primary glomerulonephritis was the diagnose of patients whose glomerular filtration rate (GFR) 30-89 mL/min/1.73m2, classification of CKD was between 2 and 3 and was none infectious and non-dialysis patients. Diagnostic criteria for CKD was according to KDOQI (Kidney Disease Outcomes Quality Initiative) clinical practice guideline. Patients who has symptoms of fatigue, soreness of loins, sticky and thick coating, soft and string pulse contribute to syndrome of spleen and kidney qi deficiency and dampness heat.

Exclusion criteria

Exclusion criteria: Patients were secondary glomerulonephritis (systemic lupus erythema, allergic purpura, hepatitis b, diabetes) and were pregnancy or breast-feeding women, or were allergic to this medicine.

Design outcomes

Primary

MeasureTime frame
24 hour urinary protein;Estimates of glomerular filtration rate;serum creatinine;serum urea nitrogen;

Countries

China

Contacts

Public ContactSu Zhonghao
suzh88@126.com+86 021 51322250

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026